The story of Sildenafil presents a intricate picture for shareholders. While the initial launch generated significant profits, the lapse of its exclusive rights opened the avenue to generic versions, dramatically https://bookmarkindexing.com/story21516004/sildenafil-and-the-pharmaceutical-industry-a-risky-opportunity